Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Cybin UK Ltd. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and a corresponding number of art units. This distribution shows that each pending matter is being handled by a different individual in a different administrative section. Examiner YOUNG, MICAH PAUL is identified as the busiest examiner, though they are only responsible for 1 pending office action.
This 1 action is part of the total workload. The variety of administrative sections suggests that the company's filings cover diverse technical sub-sectors within the broader Biotechnology & Pharmaceuticals field. Managing multiple examiners across various units requires a coordination effort to ensure consistency. The company must adapt its prosecution strategy to the specific requirements and examiner tendencies found in each separate environment for its pending matters. Practitioners should monitor the specific habits of YOUNG, MICAH PAUL while also tracking the other active files. This decentralized structure means that the outcome of one case may not necessarily predict the results of the others.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (33%) |
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOUNG, MICAH PAUL | 1 | 55.2% | +30.0% |
| PURDY, KYLE A | 1 | 41.0% | +35.7% |
| GONZALEZ, LUISALBERTO | 1 | 59.7% | +46.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18748483 | THERAPEUTIC SOLID DOSAGE FORMS | YOUNG, MICAH PAUL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18748483 | THERAPEUTIC SOLID DOSAGE FORMS | YOUNG, MICAH PAUL | — |
| 18711130 | INJECTABLE AND INHALABLE FORMULATIONS | PURDY, KYLE A | — |
| 18619547 | METHOD OF ADMINISTRATION | GONZALEZ, LUISALBERTO | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| 1611 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18748483 | THERAPEUTIC SOLID DOSAGE FORMS | YOUNG, MICAH PAUL | 1618 | §101Other | Final Rejection | — | Pending | Jun 20, 2024 |
| 18711130 | INJECTABLE AND INHALABLE FORMULATIONS | PURDY, KYLE A | 1611 | §103§112DP | Non-Final OA | — | Pending | May 17, 2024 |
| 18619547 | METHOD OF ADMINISTRATION | GONZALEZ, LUISALBERTO | 1624 | §103 | Non-Final OA | — | Pending | Mar 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCybin UK Ltd. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Micah Paul Young has the most, with 1 of Cybin UK Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
